{
    "clinical_study": {
        "@rank": "116049", 
        "arm_group": {
            "arm_group_label": "Coronary MR Angiography (CMRA)", 
            "arm_group_type": "Other", 
            "description": "Coronary MR Angiography(CMRA). A gadolinium-based contrast (Optimark or MultiHance) will be administered as well as a beta blocker which will be assigned based upon heart rate."
        }, 
        "brief_summary": {
            "textblock": "This is a pilot study to determine whether coronary magnetic resonance angiography(CMRA)can\n      identify adverse plaque characteristics (buildup of fat, cholesterol, calcium, and other\n      substances found in the blood) seen on  coronary computed tomography angiography(CCTA) and\n      evaluate whether there is a relationship between the adverse plaque characteristics and the\n      presence of coronary artery wall inflammation."
        }, 
        "brief_title": "Identification of Adverse Plaque Characteristics by Coronary MR Angiography", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "This pilot study will examine 20 stable patients who have undergone a clinically-indicated\n      coronary computed tomography angiography (CCTA) for suspected Coronary Artery Disease.  They\n      will be invited to undergo a research coronary Magnetic Resonance Imaging scan with\n      contrast(CMRA). Based upon the subject's heart rate, a beta blocker may be administered as\n      its use has been shown to be effective in producing better images as it widens the arteries.\n\n      Researchers will use newly developed non-invasive coronary MRA techniques to compare\n      information shown on the research CMRA with the clinical CCTA. While CCTA has been\n      demonstrated to be able to provide data on adverse plaque characteristics (APC's), the\n      ability of CMRA to evaluate these features is not established."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518 years\n\n          -  Ability to comprehend and sign informed consent\n\n          -  Presence of a non-calcified or mixed plaque without high-grade stenosis in the left\n             main or a proximal coronary artery segment AND at least one APC present in this\n             plaque by CCTA (defined as LAP with <30 Hounsfield units or PR with \u226510% increase in\n             the maximal vessel diameter within the plaque as compared to a proximal reference\n             segment as previously described10).\n\n        Exclusion Criteria:\n\n          -  High-grade stenosis (\u226550% stenosis of the left main artery or \u226570% stenosis  of\n             another proximal coronary segment);\n\n          -  Coronary artery stent in the segment with the reference plaque\n\n          -  Possible pregnancy\n\n          -  Glomerular filtration rate <45 ml/min\n\n          -  More than 90 days between CCTA and CMRA study\n\n          -  Any significant arrhythmia (e.g. atrial fibrillation, frequent ectopy)\n\n          -  Significant asthma\n\n          -  History of 2nd or 3rd degree  heart block\n\n          -  Allergy or known intolerance to beta-blockers\n\n          -  Use of phosphodiesterase inhibitor (e.g. Viagra) within the last 48 hours\n\n          -  Rapid heart rate (heart rate \u226590 beats/minute)\n\n          -  Severe aortic stenosis (Aortic valve area <1.0 cm2 or mean gradient >30 mmHg)\n\n          -  Systolic blood pressure <100 mmHg\n\n          -  Other contraindication to MRI, including metallic implants (valve replacement,\n             pacemaker, implantable cardiac defibrillator, metallic spine material), intracranial\n             clips, metallic fragments in eyes, and claustrophobia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986868", 
            "org_study_id": "27850"
        }, 
        "intervention": {
            "arm_group_label": "Coronary MR Angiography (CMRA)", 
            "description": "Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.", 
            "intervention_name": "Coronary MR Angiography (CMRA)", 
            "intervention_type": "Other", 
            "other_name": [
                "MRI with contrast", 
                "MultiHance", 
                "Optimark", 
                "Gadolinium-based contrast", 
                "MRA", 
                "MR Imaging", 
                "MR angiography"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Coronary Magnetic Resonance Angiography", 
            "CMRA", 
            "MRI with contrast", 
            "MultiHance", 
            "Optimark", 
            "Gadolinium-based contrast", 
            "MRA", 
            "MR angiography"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "contact": {
                "email": "bermand@cshs.org", 
                "last_name": "Daniel S Berman, MD", 
                "phone": "310-423-4223"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90048"
                }, 
                "name": "Cedars-Sinai Medical Center"
            }, 
            "investigator": {
                "last_name": "Daniel S Berman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Identification of Adverse Plaque Characteristics by Coronary Magnetic Resonance Angiography", 
        "overall_contact": {
            "email": "bermand@cshs.org", 
            "last_name": "Daniel S Berman, MD", 
            "phone": "310 423-4223"
        }, 
        "overall_contact_backup": {
            "email": "littmanr@cshs.org", 
            "last_name": "Rhona Littman", 
            "phone": "310 423-4387"
        }, 
        "overall_official": {
            "affiliation": "Cedars-Sinai Medical Center", 
            "last_name": "Daniel S Berman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Adverse plaque characteristics present on CMRA", 
            "safety_issue": "No", 
            "time_frame": "one day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986868"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cedars-Sinai Medical Center", 
            "investigator_full_name": "Daniel S. Berman", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Cedars-Sinai Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cedars-Sinai Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}